Mycobacteria, such as M. leprae and M. tuberculosis infect billions of humans. However, because of appropriate immune responses and antibiotic therapy, overt mycobacterial diseases occur far less frequently. M. avium subspecies paratuberculosis (MAP) causes Johne's disease in ruminants, an affliction evocative of inflammatory bowel disease (IBD). Several agents used to treat IBD (5-ASA, methotrexate, azathioprine and its metabolite 6-MP) have recently been shown to be antiMAP antibiotics. We herein evaluate the prevalence of MAP DNA in healthy individuals and compare them with IBD patients on antiMAP antibiotics.
We studied 100 healthy individuals (90 blood donors) and 246 patients with IBD. IS900 MAP DNA was identified using a nested primer PCR in the buffy coat of blood. Positive signal was confirmed as MAP by DNA sequence analysis. PCR positive results frequencies were compared according to medications used. Significance was accepted at p<0.05.
47% (47/100) healthy controls and 16% (40/246) IBD patients were IS900 positive (p<0.0001). MAP DNA was identified in 17% of 143 patients receiving mesalamine and 6% of 16 receiving sulfasalazine. None of the IBD patients receiving methotrexate (n = 9), 6-MP (n = 3), ciprofloxacin (n = 5) or Tacrolimus® (n = 3) had MAP DNA detectable in their blood.
We found a disquietingly large percentage of healthy individuals have MAP DNA in their blood, the significance of which remains to be determined. Counter-intuitively, the incidence of MAP DNA was significantly lower in patients with IBD. Agents with the most potent in vitro antiMAP activity were associated with clearance of blood MAP DNA. We posit that the use antiMAP antibiotics was responsible for the decreased prevalence of MAP DNA in patients with IBD.
Citation: Juste RA, Elguezabal N, Garrido JM, Pavon A, Geijo MV, Sevilla I, et al. (2008) On the Prevalence of M. avium Subspecies paratuberculosis DNA in the Blood of Healthy Individuals and Patients with Inflammatory Bowel Disease. PLoS ONE 3(7): e2537. doi:10.1371/journal.pone.0002537
Editor: Floyd Romesberg, The Scripps Research Institute, United States of America
Received: February 27, 2008; Accepted: May 21, 2008; Published: July 2, 2008
Copyright: © 2008 Juste et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by an ETORTEK grant from the Departamento de Industria, Comercio y Turismo of the Gobierno Vasco. A.I. was supported by a Marie Curie European Reintegration Grant (MERG-CT-2004-004323) within the 6th European Community RTD Framework Programme. Sponsors have not participated in the design or execution of any part of this manuscript.
Competing interests: RAJ. is President of the International Paratuberculosis Association. He has had expenses paid by a company for giving a conference, attending a meeting and making an expert report for registration of a vaccine against paratuberculosis. NEIKER has received funding for a study on the efficacy of paratuberculosis vaccination in cattle. RAJ, NEL, JGA, MVG and ISE are involved with a small company that is an spin-off of NEIKER in a project for the development of an improved vaccine for paratuberculosis. RJG has submitted patents on some of the hypotheses addressed in this and prior manuscripts. There are no potential conflicts of interest for the other authors.
In humans, mycobacteria often colonize without causing overt disease. In India 5% (equivalent to ∼65 million) of the population shed M. leprae DNA in their nasal secretions , although <400,000 have clinical leprosy.  Similarly, the number of individuals who have “latent” tuberculosis (30% of humankind) far exceeds the number with clinically evident tuberculosis. , 
M. avium subspecies paratuberculosis (MAP) causes a chronic wasting enteritis in ruminants called Johne's disease  that is highly evocative of Crohn's disease (CD).  Prevailing medical dogma  considers that MAP is not zoonotic.  Yet it is of great concern that humans worldwide are continually exposed to viable MAP. MAP has been cultured from USA chlorinated potable municipal water , pasteurized milk in the USA , and Europe  , breast milk of mothers with CD  and from the blood of patients with inflammatory bowel disease (IBD).  Intriguingly, although Koch's postulates  may already have been met for MAP and CD  they have still not been met for M. leprae and leprosy. 
We posit that the pivotal reason that MAP has not been acknowledged as a human pathogen is that, unknowingly, the medical profession has been treating MAP since 1942, when sulfasalazine was introduced.  Until recently, it was unrecognized that the “anti-inflammatory” 5 amino salicylic acid (5-ASA)  and the “immune modulators” methotrexate , azathioprine  and its metabolite 6 mercapto-purine (6-MP) ,  are antiMAP antibiotics. We concluded that all antecedent studies evaluating the potential zoonotic character of MAP need to be reevaluated, as their control groups were not placebo. ,
We hypothesized that MAP may asymptomatically colonize apparently healthy individuals. We further hypothesized that the unwitting use of antiMAP antibiotics may be associated with a decrease in the incidence of MAP in patients with IBD. Accordingly, we evaluated the blood of healthy individuals and IBD patients treated with antiMAP agents for the presence of MAP DNA.
The Ethics Committee from each institution approved this study. Every participant signed an Informed Consent form that was in compliance with all relevant national and European Union regulations. There were no therapeutic interventions or alterations in the concurrent therapy, or initiation of therapy, as a consequence of participation.
The Control group comprised 100 subjects. The majority were healthy blood donors (HBD) recruited from a regional Basque Country Blood Bank. They had met all European Union requirements for allogenic blood donation, and each denied major infections or concomitant active disease. None gave any history of gastrointestinal disease. The remainder of the Controls were healthy laboratory workers from the same region.
The IBD group consisted of 246 subjects recruited from three hospitals in the Basque Country in Northern Spain; The Quirón Donostia Clinic in Gipuzkoa (65), the Hospital de Txagorritxu in Araba (81), and the Hospital de Galdakao in Bizkaia (100) The clinical diagnosis of IBD had been predetermined by each treating physician. Patients were stratified into Crohn's disease, (CD), ulcerative colitis (UC) or Indeterminate Colitis (IC) by clinical histories and routine endoscopic, histological, and radiographic criteria. Current disease status and concurrent treatment were documented on a standardized eight item, 54 choice questionnaire that was completed by each patient with the physician's help.
Three 4 mL whole blood tubes were obtained from each subject (two sterile EDTA and one heparin-lithium Vacutainer® tubes (BD)). All blood samples were coded to conceal the patient's identity and diagnosis to laboratory workers. All samples were processed within 4 hours after extraction in a class II bio-safety cabinet.
Genomic DNA was extracted from buffy coat cells. Briefly, one volume blood was incubated with one volume 155 mM ammonium chloride for 20 minutes to lyse the red blood cells. The tube was centrifuged (10 mins. 200×g) the cell pellet washed twice with PBS, recentrifuged (10 mins. 200×g). DNA was extracted and purified (QIAamp DNA Blood Mini Kit (QIAGEN GmbH, Hilden, Germany) and stored at −20°C until amplified.
Nested PCR was used to amplify IS900 as described.  In brief, the first round primers (P90 and P91) amplify a 398 bp fragment and the second set (AV1 and AV2) identify a 298 bp fragment. For the first round, 10 µl of genomic DNA were added to 40 µl of PCR buffer mixture. The PCR buffer mixture consisted of 5 mM MgCl2, 0.2 mM dNTP, 6% DMSO, 2 µM primers and 2.5 U of Taq Polymerase (Invitrogen Ltd., Paisley, UK). In the second round, all conditions were the same except that 5 µl of the PCR product from the first round were used as DNA template. PCR cycling conditions were: 95°C for 5 min, 34 cycles of: 95°C for 1 min, 58°C for 1.5 min, 72°C for 1.5 min, with a final extension phase of 10 min at 72°C. Amplification products were separated using 2% agarose gel electrophoresis (150 volts; 50 mins). The positive MAP control was ATCC 19698 DNA and the negative controls were distilled water, identically processed with the clinical samples. A band co-migrating with the ATCC 19698 DNA at the predicted amplicon size of 298-bp was considered positive.
The identity of the amplified 298 bp amplicon was confirmed from two positive healthy controls and 2 IBD patients. Bands were excised, extracted, purified (GFX PCR DNA and Gel Band purification kit. Amersham Biosciences, Buckinghamshire, UK) and commercially sequenced (Centro Superior de Investigaciones Científicas, Madrid, Spain). The sequence identity of the final 298 bp. amplicon was compared with Genebank accession X16293 sequence for MAP IS900 using BLAST (NLM) and sequence alignment analyses.
Contamination Avoidance Procedures
Stringent controls were adopted to minimize the possibility of contamination. These include using a Level II Bio-safety hood to process buffy coat for DNA extraction and using separate uniforms, rooms, pipettes and thermocyclers for the primary and the secondary rounds of PCR amplification.
Comparisons of MAP DNA in blood frequencies for overall IBD, IBD type, lesion location and type of treatment were made using the Fisher's exact test (SAS Institute Inc., Cary, NC 27513, USA). Treatments were grouped by chemical structure or presumed mechanism of action in three categories: anti-inflammatories or salycilic acid derivatives (SAD) (mesalamine and sulfasalazine), immuno-modulators (azathioprine, 6-mercaptopurine, methotrexate and Tacrolimus®) and conventional antibiotics (metronidazol and ciprofloxacin). Statistical significance was accepted at p<0.05.
Of the 100 Controls in this study, 90 were healthy human blood donors and 10 healthy laboratory workers. The majority of IBD subjects (54%; 132/246) had CD, 42% (103/246) had UC and 3% (8/246) had IC. As a group the CD were the youngest, and IC the oldest (Table 1). When anatomical location of maximal pathology was reported, a minority (5%; 6/116) of CD subjects had disease confined to the colon (Data not presented). Among subjects with UC, a minority (42%; 38/92) had ulcerative proctitis (Data not presented).
The PCR data (Figure 1) shows bands that co-migrate with the positive control at the predicted amplicon size of 298 bp. The sequenced DNA of the representative sample bands from each clinical subset (Controls and IBD) showed >99% identity in all cases with the Genebank accession X16293 sequence for MAP IS900 (Data not presented).
Shown are representative samples of IBD patients and Controls. M = molecular weight marker, lane A = negative control of first round of PCR, lane B = negative control of second round of PCR, + = DNA from MAP strain ATCC 19698.
Forty seven % (47/100) of the controls [47% (42/90) blood donors and 50% (5/10) healthy laboratory workers] had a band with the predicted 298 bp amplicon (Figures 1 & 2). In contrast, 16% (40/246) IBD patients had the 298 bp amplicon (p<0.0001 compared to Controls) (Figures 1 & 2). There were no significant differences when stratified by IBD diagnosis or location of maximal pathology (Data not presented).
We next stratify IBD patients by the class of medication that they were taking. “SAD” = salicylic acid derivatives. “Anti-metabolites” were 6-MP and its precursor azathioprine, methotrexate and the “immuno-suppressive” Tacrolimus®. The conventionally accepted antibiotics used in this study were ciprofloxacin and metronidazole. The % MAP DNA positive are shown on the ordinate. The total number of 270 is greater than the number of IBD subjects (246) because some individuals were getting multiple medications and some (37) were receiving no medications at all. All IBD patients, whether combined or sub-stratified are significantly different from the non-IBD controls.
When comparing the prevalence of MAP DNA in each group of drugs to the Controls, conventional anti-inflammatories (p<0.0001), immuno-modulators (p<0.0001) and antibiotics (p = 0.0293) were significantly less likely to have MAP DNA in their blood. For IBD patients receiving “No medications,” MAP DNA prevalence was slightly higher (22% compared to 15% for all IBD subjects combined). However, all IBD subsets were significantly lower than the non-IBD control group. (Figure 2 Right hand columns).
Finally, within each chemical group or class of agents, we evaluated individual medications. As a caveat, although these data were collected prospectively, the analysis is post hoc and the numbers are small.
The SAD “Anti-inflammatories” were sulfasalazine and mesalamine. 17% receiving mesalamine (103 on mesalamine/143 not on mesalamine) were MAP DNA positive. Among those receiving sulfasalazine, 6% (16 on sulfasalazine/230 not on sulfasalazine) were MAP DNA positive (Figure 3).
The control group comprises all IBD patients who were NOT receiving the agent identified. Mesalamine® is a proprietary name for 5-ASA. Sulfasalazine is a conjugate of 5-ASA and the antibiotic sulfapyridine. Although only 16 patients were taking sulfasalazine, the incidence of MAP DNA is significantly less than in the IBD group as a whole.
The “Immuno-modulators” prescribed were azathioprine, its metabolite 6-MP, methotrexate and Tacrolimus®. With azathioprine 18% were MAP DNA positive, similar to controls (50 on azathioprine/196 not on azathioprine). In contrast, no MAP DNA was detected when either 6-MP (3 on 6-MP/ 243 not on 6-MP), methotrexate (9 on methotrexate; 237 not on methotrexate) or Tacrolimus (3 on Tacrolimus; 243 not on Tacrolimus) were used (Figure 4).
  The control group comprises all IBD patients who were NOT receiving the agent identified. The majority were receiving the precursor of 6-MP, azathioprine. No MAP DNA is found when 6-MP, methotrexate and Tacrolimus are used.
The conventional antibiotics prescribed were metronidazole and ciprofloxacin. Twenty five per cent of patients receiving metronidazole were MAP DNA positive (12 on metronidazole; 234 not on metronidazole). In contrast, none of the patients on ciprofloxacin (5 on ciprofloxacin; 241 not on ciprofloxacin) were MAP DNA positive (Figure 5).
There was no MAP DNA detected in the small number of patients taking ciprofloxacin.
Steroid therapy had no effect on the presence of MAP DNA (16%) when combined (any steroid n = 44/no steroids n = 202) or individual steroids were studied (Figure 6). “Disease Activity” data were available for 98% (240/246) of IBD patients. There was no difference in the presence or absence of MAP DNA when analysed according to disease activity and/or concomitant medication usage at the time of phlebotomy (Figure 7).
There are no significant differences noted.
For the remaining 6 patients “Disease Activity” data were not provided on their questionnaire. In this post hoc analysis, with group sizes that are not comparable, there is no difference in the presence or absence of MAP DNA among the groups. Our questionnaire did NOT obtain information on medications that had been used PRIOR to the day of phlebotomy.
The presence of MAP DNA does not address potential MAP viability, anymore than the presence of M. leprae DNA in nasal secretions  determines possible M. leprae infectivity. Nevertheless, our data shows a disquietingly high 47% of healthy individuals have MAP DNA in their blood. These data thus corroborate and extend a prior study showing 20% MAP DNA positivity in non-IBD subjects.  We conclude that the possible viability of MAP in blood, that may have allogenic use, should be expeditiously clarified.
“Anti-inflammatory” (5-ASA), “immuno-modulatory” agents (azathioprine its metabolite 6-MP and methotrexate) and the “immuno-suppressive” agent Tacrolimus® are used to treat IBD and multiple “inflammatory” and “autoimmune” diseases. This is despite the fact that the “mechanism of action (of 5-ASA) in the therapy of IBD is unclear”  and all are used simply because of empirical efficacy. In this study, we show that 5-ASA decreases the incidence of MAP DNA from the blood of patients with IBD. We additionally show that the “immuno-modulators” 6-MP and methotrexate and the “immuno-suppressive” Tacrolimus actually clear MAP DNA.
We found that all of our IBD subset groups, including those on “no active medications”, had a lower incidence of MAP DNA than the non-IBD control group (Figure 2). The most plausible explanation for the fact that IBD patients on no medication have a lower incidence of MAP DNA than the non-IBD controls is that our questionnaire did not request a history of medications that had been used by the IBD patients prior to the day of phlebotomy. Thus, those patients who were reported as being “On no medications” at the time of phlebotomy may well have been exposed to antiMAP agents in the past. (Figures 2 & 7).
Because of small numbers, our post hoc analyses should be considered as tentative. Nevertheless, our observations are compatible with the thesis that 5-ASA , azathioprine , 6-MP   and methotrexate  are acting as antiMAP antibiotics. They also corroborate our in vitro data that 5-ASA  is a far less potent antiMAP antibiotic than are 6-MP and methotrexate. 
Tacrolimus  is an “immuno-suppressive” medication most used to prevent organ transplant rejection  and more recently in the therapy of IBD.  It is of considerable interest that Tacrolimus is from the macrolide antibiotic family of medications , amongst the most potent anti M. avium antibiotic families. 
Ciprofloxacin clears MAP DNA. This is an antibiotic, which has shown an activity against different strains of MAP “in vitro.”  In contrast, metronidazole an alternative antibiotic used in this study does not clear MAP DNA. Our data suggest that ciprofloxacin is a more effective antiMAP antibiotic than is metronidazole. These initial observations provide insights that should be of use when determining which agents should be evaluated when designing future, pivotal, clinical trials.
The use of the TNF alpha antagonist Infliximab® is associated with reactivation of latent tuberculosis and requires concomitant use of anti-tuberculosis prophylaxis. We find only 9% (2/13) of our patients treated with infliximab are MAP DNA positive. Our observations are therefore at variance with the 80% (4/5) culture of MAP from the blood of patients who were receiving infliximab in a prior study.  The most plausible explanation for these discrepant observations are the potent antiMAP agents that were concomitantly used in our patients. (Table 2). Prudence suggests that, until the potential MAP zoonosis conundrum is finally resolved, any individual being treated with TNF alpha antagonists, for any disease, should continue to receive antiMAP agents such as 5-ASA, sulfasalazine, methotrexate, 6-MP, ciprofloxacin, Tacrolimus or another macrolide antibiotics.
When steroids are used to treat the inflammatory reaction in tuberculosis, anti-tuberculosis medications are always co-administered. ,  MAP has been cultured from 60% (3/5) IBD patients receiving steroids.  However, our data do not show an increase in the incidence of MAP DNA when steroids are used. Again, the most reasonable explanation is the potent antiMAP agents that were co-administered in our patients being given steroids. We conclude that caution suggests that whenever steroids are used in the therapy of IBD, concomitant antiMAP agents should always be used.
If MAP zoonosis is accepted, MAP antibiotic susceptibility studies will need to be performed. However, few laboratories can successfully culture the cell wall deficient form of MAP that exists in humans , , , a process that may take up to 18 months.  Nucleic acid based methods, to more rapidly determine the presence of MAP RNA (indicating viability) , potential infectivity   and antibiotic susceptibility  may need to be developed. Our data suggest that until such nucleic acid based methodologies are available, identifying MAP DNA prior to, and its clearance following initiation of antiMAP therapy, may provide the most readily available practicable surrogate to in vitro MAP antibiotic susceptibility information.
Conceived and designed the experiments: RG RJ JG IO. Performed the experiments: NE JG AP MG IS RC AI. Analyzed the data: RJ. Contributed reagents/materials/analysis tools: NE AP MG JC AT FG RC AI. Wrote the paper: RG.
- 1. Ramaprasad P, Fernando A, Madhale S, Rao JR, Edward VK, et al. (1997) Transmission and protection in leprosy: indications of the role of mucosal immunity. Lepr Rev 68: 301–315.
- 2. Britton WJ, Lockwood DN (2004) Leprosy. Lancet 363: 1209–1219.
- 3. 2003 WHO annual report on global TB control–summary. Wkly Epidemiol Rec 78: 122–128.
- 4. Corbett EL, Watt CJ, Walker N, Maher D, Williams BG, et al. (2003) The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 163: 1009–1021.
- 5. Johne HA, Frothingham L (1895) Ein eigenthumlicher fall von tuberculose beim rind ( A particular case of tuberculosis in a cow). Dtsch Zeitschr Tiermed, Vergl Pathol 21: 438–454.
- 6. Dalziel TK (1913) Chronic intestinal enteritis. British Medical Journal ii: 1068–1070.
- 7. Selby W, Pavli P, Crotty B, Florin T, Radford-Smith G, et al. (2007) Two-year combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine for Crohn's disease. Gastroenterology 132: 2313–2319.
- 8. Greenstein RJ, Collins MT (2004) Emerging pathogens: is Mycobacterium avium subspecies paratuberculosis zoonotic? Lancet 364: 396–397.
- 9. Mishina D, Katsel P, Brown ST, Gilberts EC, Greenstein RJ (1996) On the etiology of Crohn disease. Proc Natl Acad Sci U S A 93: 9816–9820.
- 10. Ellingson JL, Anderson JL, Koziczkowski JJ, Radcliff RP, Sloan SJ, et al. (2005) Detection of viable Mycobacterium avium subsp. paratuberculosis in retail pasteurized whole milk by two culture methods and PCR. J Food Prot 68: 966–972.
- 11. Grant IR, Hitchings EI, McCartney A, Ferguson F, Rowe MT (2002) Effect of Commercial-Scale High-Temperature, Short-Time Pasteurization on the Viability of Mycobacterium paratuberculosis in Naturally Infected Cows' Milk. Appl Environ Microbiol 68: 602–607.
- 12. Ayele WY, Svastova P, Roubal P, Bartos M, Pavlik I (2005) Mycobacterium avium subspecies paratuberculosis cultured from locally and commercially pasteurized cow's milk in the Czech Republic. Appl Environ Microbiol 71: 1210–1214.
- 13. Naser SA, Schwartz D, Shafran I (2000) Isolation of Mycobacterium avium subsp paratuberculosis from breast milk of Crohn's disease patients. Am J Gastroenterol 95: 1094–1095.
- 14. Naser SA, Ghobrial G, Romero C, Valentine JF (2004) Culture of Mycobacterium avium subspecies paratuberculosis from the blood of patients with Crohn's disease. Lancet 364: 1039–1044.
- 15. Koch R (1882) Die Aetilogie der Tuberculose. Berl, klin, Wschr 19: 221–230.
- 16. Greenstein RJ (2003) Is Crohn's disease caused by a mycobacterium? Comparisons with leprosy, tuberculosis, and Johne's disease. Lancet Infect Dis 3: 507–514.
- 17. Stewart-Tull DES (1982) Mycobacterium leprae - The bacteriologist's enigma. In: Ratledge C, Stanford J, editors. The Biology of the Mycobacteria, Volume 1: Physiology, Identification, and Classification. 1 ed. New york: Academic Press. pp. 273–307.
- 18. Svartz N (1942) Salazopyrin, a new sulfanilamide preparation. A. Therapeutic Results in Rheumatic Polyarthritis. B. Therapeutic Results in Ulcerative Colitis. C. Toxic Manifestations in Treatment with Sulfanilamide Preparations. Acta Medica Scandinavica 110: 577–598.
- 19. Greenstein RJ, Su L, Shahidi A, Brown ST (2007) On the Action of 5-Amino-Salicylic Acid and Sulfapyridine on M. avium including Subspecies paratuberculosis. PLoS ONE 2: e516.
- 20. Greenstein RJ, Su L, Haroutunian V, Shahidi A, Brown ST (2007) On the Action of Methotrexate and 6-Mercaptopurine on M. avium Subspecies paratuberculosis. PLoS ONE 2: e161.
- 21. Shin SJ, Collins MT (2008) Thiopurine drugs (azathioprine and 6-mercaptopurine) inhibit Mycobacterium paratuberculosis growth in vitro. Antimicrob Agents Chemother 52: 418–426.
- 22. Berardi RR (1996) Inflammatory Bowel Disease. In: Herfindal ET, Gourley DR, editors. Textbook of Therapeutics Drugs and Disease Management. Baltimore: Williams and Wilkins. pp. 483–502.
- 23. Kino T, Hatanaka H, Hashimoto M, Nishiyama M, Goto T, et al. (1987) FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics. J Antibiot (Tokyo) 40: 1249–1255.
- 24. Spencer CM, Goa KL, Gillis JC (1997) Tacrolimus. An update of its pharmacology and clinical efficacy in the management of organ transplantation. Drugs 54: 925–975.
- 25. Ng SC, Arebi N, Kamm MA (2007) Medium-term results of oral tacrolimus treatment in refractory inflammatory bowel disease. Inflamm Bowel Dis 13: 129–134.
- 26. Barrow WW, Wright EL, Goh KS, Rastogi N (1993) Activities of fluoroquinolone, macrolide, and aminoglycoside drugs combined with inhibitors of glycosylation and fatty acid and peptide biosynthesis against Mycobacterium avium. Antimicrob Agents Chemother 37: 652–661.
- 27. Zanetti S, Molicotti P, Cannas S, Ortu S, Ahmed N, et al. (2006) “In vitro” activities of antimycobacterial agents against Mycobacterium avium subsp. paratuberculosis linked to Crohn's disease and paratuberculosis. Ann Clin Microbiol Antimicrob 5: 27.
- 28. Prasad K, Volmink J, Menon GR (2000) Steroids for treating tuberculous meningitis. Cochrane Database Syst Rev CD002244.
- 29. Farinha NJ, Razali KA, Holzel H, Morgan G, Novelli VM (2000) Tuberculosis of the central nervous system in children: a 20-year survey. J Infect 41: 61–68.
- 30. Chiodini RJ, Van Kruiningen HJ, Merkal RS, Thayer WR Jr., Coutu JA (1984) Characteristics of an unclassified Mycobacterium species isolated from patients with Crohn's disease. J Clin Microbiol 20: 966–971.
- 31. Bull TJ, McMinn EJ, Sidi-Boumedine K, Skull A, Durkin D, et al. (2003) Detection and verification of Mycobacterium avium subsp. paratuberculosis in fresh ileocolonic mucosal biopsy specimens from individuals with and without Crohn's disease. J Clin Microbiol 41: 2915–2923.
- 32. Ivnitski D, O'Neil DJ, Gattuso A, Schlicht R, Calidonna M, et al. (2003) Nucleic acid approaches for detection and identification of biological warfare and infectious disease agents. Biotechniques 35: 862–869.
- 33. Sampath R, Hall TA, Massire C, Li F, Blyn LB, et al. (2007) Rapid identification of emerging infectious agents using PCR and electrospray ionization mass spectrometry. Ann N Y Acad Sci 1102: 109–120.
- 34. Lindler LE, Fan W (2003) Development of a 5′ nuclease assay to detect ciprofloxacin resistant isolates of the biowarfare agent Yersinia pestis. Mol Cell Probes 17: 41–47.